Pays: Irlande
Langue: anglais
Source: HPRA (Health Products Regulatory Authority)
CARBOCISTEINE
Pierre Fabre Medicament
CARBOCISTEINE
250/5 Mg/Ml
Oral Solution
Product not subject to medical prescription
Withdrawn
2010-11-25
IRISH MEDICINES BOARD ACT 1995 MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998 (S.I. NO.142 OF 1998) PA0329/009/001 Case No: 1999987 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PIERRE FABRE MEDICAMENT 45, PLACE ABEL GANCE, F-92654 BOULOGNE, CEDEX, , FRANCE an authorisation, subject to the provisions of the said Regulations, in respect of the product PECTRODRILL FOR CHESTY COUGHS 250MG/5ML ORAL SOLUTION The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 24/03/2006 until 23/03/2011 . Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 24/03/2006_ _CRN 1999987_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT PectoDrill for chesty coughs 250mg/5ml oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Carbocisteine 5.00g per 100ml Each 5ml contains 250mg carbocisteine For excipients, see 6.1 3 PHARMACEUTICAL FORM Oral solution A yellow to light brown, clear syrup with a weak odour suggesting caramel. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mucolytic agent for use in lower respiratory tract disorders characterised by excessive or viscous mucus. 4.2 POSOLOGY AND METHOD OF ADMINSTRATION Oral route ADULTS AND CHILDREN 12 YEARS AND OVER: The usual dose is three 5ml three times daily initially, reducing t Lire le document complet